ME02063B - Protutijela koja se vezu na tgf-alfa i epiregulin - Google Patents
Protutijela koja se vezu na tgf-alfa i epiregulinInfo
- Publication number
- ME02063B ME02063B MEP-2015-48A MEP201548A ME02063B ME 02063 B ME02063 B ME 02063B ME P201548 A MEP201548 A ME P201548A ME 02063 B ME02063 B ME 02063B
- Authority
- ME
- Montenegro
- Prior art keywords
- seq
- amino acid
- antibody according
- acid sequence
- heavy chain
- Prior art date
Links
- 102000007134 Epiregulin Human genes 0.000 title claims 2
- 101800000155 Epiregulin Proteins 0.000 title claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472338P | 2011-04-06 | 2011-04-06 | |
| PCT/US2012/030802 WO2012138510A1 (en) | 2011-04-06 | 2012-03-28 | Antibodies that bind tgf-alpha and epiregulin |
| EP12712049.1A EP2694547B1 (en) | 2011-04-06 | 2012-03-28 | Antibodies that bind tgf-alpha and epiregulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02063B true ME02063B (me) | 2015-05-20 |
Family
ID=45929050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-48A ME02063B (me) | 2011-04-06 | 2012-03-28 | Protutijela koja se vezu na tgf-alfa i epiregulin |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8613921B2 (enExample) |
| EP (1) | EP2694547B1 (enExample) |
| JP (1) | JP2014515743A (enExample) |
| KR (1) | KR101581517B1 (enExample) |
| CN (1) | CN103459423B (enExample) |
| AR (2) | AR085484A1 (enExample) |
| AU (1) | AU2012240508B2 (enExample) |
| BR (1) | BR112013023513A2 (enExample) |
| CA (1) | CA2832256C (enExample) |
| CY (1) | CY1116332T1 (enExample) |
| DK (1) | DK2694547T3 (enExample) |
| EA (1) | EA024921B1 (enExample) |
| ES (1) | ES2539503T3 (enExample) |
| HR (1) | HRP20150468T1 (enExample) |
| IL (1) | IL228101A0 (enExample) |
| ME (1) | ME02063B (enExample) |
| MX (1) | MX2013011596A (enExample) |
| PL (1) | PL2694547T3 (enExample) |
| PT (1) | PT2694547E (enExample) |
| RS (1) | RS54000B1 (enExample) |
| SG (1) | SG193452A1 (enExample) |
| SI (1) | SI2694547T1 (enExample) |
| TW (1) | TWI454481B (enExample) |
| UA (1) | UA110051C2 (enExample) |
| WO (1) | WO2012138510A1 (enExample) |
| ZA (1) | ZA201306813B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4045641A1 (en) | 2019-10-15 | 2022-08-24 | Eli Lilly and Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| TWI807338B (zh) * | 2020-06-26 | 2023-07-01 | 美商美國禮來大藥廠 | 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途 |
| KR102495473B1 (ko) * | 2020-10-06 | 2023-02-06 | 서울대학교병원 | 앰피레귤린을 유효성분으로 포함하는 안질환 치료용 조성물 |
| TWI859538B (zh) | 2021-05-21 | 2024-10-21 | 美商美國禮來大藥廠 | 靶向表皮調節素(epiregulin)之化合物及方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5190858A (en) | 1989-02-01 | 1993-03-02 | Oncogene Science, Inc. | Monoclonal antibodies directed to epitopes of human transforming growth factor--α and uses thereof |
| WO2008044068A2 (en) | 2006-10-11 | 2008-04-17 | Fusion Antibodies Limited | Combination therapy |
| CN101594883B (zh) * | 2006-10-12 | 2018-04-10 | 中外制药株式会社 | 使用抗ereg抗体的癌症的诊断和治疗 |
| GB0807018D0 (en) | 2008-04-17 | 2008-05-21 | Fusion Antibodies Ltd | Antibodies and treatment |
| US20120141501A1 (en) * | 2009-05-29 | 2012-06-07 | Forerunner Pharma Research Co. Ltd | Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component |
-
2012
- 2012-03-22 AR ARP120100945A patent/AR085484A1/es active IP Right Grant
- 2012-03-23 TW TW101110200A patent/TWI454481B/zh not_active IP Right Cessation
- 2012-03-28 CA CA2832256A patent/CA2832256C/en not_active Expired - Fee Related
- 2012-03-28 PT PT127120491T patent/PT2694547E/pt unknown
- 2012-03-28 HR HRP20150468TT patent/HRP20150468T1/hr unknown
- 2012-03-28 SG SG2013069075A patent/SG193452A1/en unknown
- 2012-03-28 MX MX2013011596A patent/MX2013011596A/es not_active Application Discontinuation
- 2012-03-28 BR BR112013023513A patent/BR112013023513A2/pt not_active IP Right Cessation
- 2012-03-28 UA UAA201311686A patent/UA110051C2/uk unknown
- 2012-03-28 KR KR1020137025929A patent/KR101581517B1/ko active Active
- 2012-03-28 RS RS20150321A patent/RS54000B1/sr unknown
- 2012-03-28 ES ES12712049.1T patent/ES2539503T3/es active Active
- 2012-03-28 JP JP2014503684A patent/JP2014515743A/ja not_active Ceased
- 2012-03-28 PL PL12712049T patent/PL2694547T3/pl unknown
- 2012-03-28 EA EA201370196A patent/EA024921B1/ru active IP Right Revival
- 2012-03-28 WO PCT/US2012/030802 patent/WO2012138510A1/en not_active Ceased
- 2012-03-28 US US13/432,204 patent/US8613921B2/en active Active
- 2012-03-28 AU AU2012240508A patent/AU2012240508B2/en not_active Ceased
- 2012-03-28 DK DK12712049T patent/DK2694547T3/en active
- 2012-03-28 CN CN201280016829.XA patent/CN103459423B/zh not_active Expired - Fee Related
- 2012-03-28 ME MEP-2015-48A patent/ME02063B/me unknown
- 2012-03-28 EP EP12712049.1A patent/EP2694547B1/en active Active
- 2012-03-28 SI SI201230160T patent/SI2694547T1/sl unknown
-
2013
- 2013-08-22 IL IL228101A patent/IL228101A0/en unknown
- 2013-09-10 ZA ZA2013/06813A patent/ZA201306813B/en unknown
-
2015
- 2015-04-17 CY CY20151100362T patent/CY1116332T1/el unknown
-
2021
- 2021-10-25 AR ARP210102953A patent/AR123912A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| HRP20160151T1 (hr) | PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| NZ595011A (en) | Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases | |
| JP2015535828A5 (enExample) | ||
| NZ608660A (en) | Anti-cd48 antibodies and uses thereof | |
| NZ609619A (en) | Novel egfr-binding molecules and immunoconjugates thereof | |
| HRP20161587T1 (hr) | Protutijela protiv bmp-6 | |
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| NZ603529A (en) | Antibodies to human gdf8 | |
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| NZ712765A (en) | Antibodies that bind csf1r | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| NZ709390A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof | |
| NZ598202A (en) | High affinity human antibodies to human angiopoietin-2 | |
| NZ598391A (en) | Anti-hepcidin antibodies and uses thereof | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PH12014500089A1 (en) | Antibodies that bind to ox40 and their uses | |
| NZ590863A (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
| SI2768859T1 (en) | Antagonists of il17c for the treatment of inflammatory disorders |